The fall COVID-19 vaccine season is starting slowly for Pfizer, with U.S. sales of its Comirnaty shots sinking 25% after federal regulators narrowed recommendations on who should get them.

Approval of updated shots also came several weeks later than usual, and Pfizer said Tuesday that hurt sales as well.

See Full Page